<?xml version="1.0" encoding="UTF-8"?>
<div class="supplementary-material" content-type="local-data" id="PMC6821460/supplementary_8" xmlns="http://www.w3.org/1999/xhtml">
 <p>Supplementary material for this article is available at 
  <div ext-link-type="uri" xlink:href="http://advances.sciencemag.org/cgi/content/full/5/10/eaax4761/DC1" xmlns:xlink="http://www.w3.org/1999/xlink">http://advances.sciencemag.org/cgi/content/full/5/10/eaax4761/DC1</div>
 </p>
 <p>Fig. S1. A microfluidic device containing cell-trapping microstructures for high-throughput analysis of single-cell infections.</p>
 <p>Fig. S2. Evaluation of 2′- 
  <i>C</i>-Me-A, a PV RdRp inhibitor. 
 </p>
 <p>Fig. S3. Translation of eGFP mRNA and activation of fluorophore are normal in the presence of GA and GS.</p>
 <p>Fig. S4 Evaluation of GS, an HSP90 inhibitor.</p>
 <p>Fig. S5 Evaluation of an antiviral drug combination: 2′-C-Me-A and GS.</p>
 <p>Fig. S6 Evaluation of inhibitor-specific signatures.</p>
 <p>Table S1. Means, SD, and 
  <i>P</i> values between groups for the 2′- 
  <i>C</i>-Me-A experiment. 
 </p>
 <p>Table S2. Means, SD, and 
  <i>P</i> values between groups for the rupintrivir experiment. 
 </p>
 <p>Table S3. Means, SD, and 
  <i>P</i> values between groups for experiments with HSP90 inhibitors. 
 </p>
 <p>Table S4. Means, SD, and 
  <i>P</i> values between groups for antiviral synergy experiments. 
 </p>
</div>
